









Markets
/
Stocks
/
nasdaq-lctx
/

Lineage Cell Therapeutics Inc

LCTX

1.550USD

+0.160+11.51%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

353.95MMarket Cap

LossP/E TTM



Lineage Cell Therapeutics Inc

1.550

+0.160+11.51%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

76 / 506

Overall Ranking

179 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.167

Target Price

+199.76%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.50M.

Fairly Valued

The company’s latest PE is -8.66, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 108.49M shares, decreasing 13.57% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.05.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 7.79, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.77M, representing a year-over-year increase of 96.38%, while its net profit experienced a year-over-year increase of 428.89%.

Score

Industry at a Glance

Previous score

7.79

Change



Financials

7.22

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.64

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.28

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -7.76, which is -14.41% below the recent high of -6.64 and -16.49% above the recent low of -9.04.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Lineage Cell Therapeutics Inc is 3.00, with a high of 9.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.167

Target Price

+199.76%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Lineage Cell Therapeutics Inc

LCTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 8.88, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 1.49 and the support level at 1.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.88

Change

0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.041

Buy

RSI(14)

76.231

Buy

STOCH(KDJ)(9,3,3)

83.169

Overbought

ATR(14)

0.085

High Vlolatility

CCI(14)

207.987

Overbought

Williams %R

13.684

Overbought

TRIX(12,20)

0.882

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.402

Buy

MA10

1.324

Buy

MA20

1.264

Buy

MA50

1.135

Buy

MA100

0.917

Buy

MA200

0.733

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Broadwood Capital, Inc.

49.56M

The Vanguard Group, Inc.

Star Investors

8.92M

+3.31%

Defender Capital LLC

6.31M

+5.83%

Raffles Capital Management, LLC

5.64M

+2.73%

Comerica, Inc.

3.00M

+275.00%

Geode Capital Management, L.L.C.

4.49M

+21.54%

BlackRock Institutional Trust Company, N.A.

10.70M

+14.13%

Renaissance Technologies LLC

Star Investors

2.29M

+0.36%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.17, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.72. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.